AstraZeneca to Cap Inhaler Costs at $35

AstraZeneca this week became the second company in recent weeks to announce it will cap the out-of-pocket costs that patients pay for its inhalers at $35. The cap is effective June 1 and will apply to the company’s entire range of inhaler products used to treat asthma and chronic obstructive pulmonary disease, including inhalers Symbicort, Breztri Aerosphere, and Airsupra. The cap will be applicable for patients who are uninsured or underinsured.

The post AstraZeneca to Cap Inhaler Costs at $35 appeared first on Pennsylvania Office of Rural Health.

Recommend0 recommendationsPublished in My Healthy Pennsylvania, Rural Health PA

Related Articles

Clinical Trial Identifies Potential Treatment for Asthma in Latino Children

Clinical trials can help researchers learn to better treat asthma – but they need diverse volunteers. Black and Latino children who have severe asthma, are prone to asthma attacks, and live in low-income urban neighborhoods are underrepresented in asthma treatment clinical trials, even though they are more likely than whites to face health inequities that …
The post Clinical Trial Identifies Potential Treatment for Asthma in Latino Children appeared first on Salud America.

Many Latino Families Struggle with Child Care Cost, Access

Child care is crucial for Latino and all families, but some face issues with access and cost.   While many Latino households with low incomes used no-cost child care, those who paid out-of-pocket tended to face very high costs, according to a new research brief from the National Research Center on Hispanic Children and Families …
The post Many Latino Families Struggle with Child Care Cost, Access appeared first on Salud America.